Mission

We are driven by our mission to develop regenerative medicines for patients suffering from devastating neurological or ocular diseases.

Pipeline

We are developing regenerative therapies for the treatment of neuronal loss-related diseases, such as Parkinson’s disease.   

Platforms

We have developed technology platforms to support our discovery.

• In vivo Cell Reprogramming Platform

• Neuroprotection Platform

People

Our team is led by pioneers of the neuronal reprogramming field, experienced AAV preclinical development and CMC experts, and experienced biotech operation and strategy experts.

Genemagic Biosciences is driven by the mission to develop regenerative medicines for patients suffering from neurological or ocular diseases. Officially launched in 2021 with a world-class leadership team, Genemagic is advancing a pipeline of regenerative therapies to regenerate neural tissues in vivo. Genemagic has offices in Shanghai, China, and Philadelphia, U.S.